The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Clinical trial NCT05170542 · UNKNOWN

Trial details

NCT number: NCT05170542
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

Start date: 2021-12-24
Primary completion: 2025-12-24
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.